A recent report by the biopharmaceutical industry shows that there are over 400 medicines and vaccines in development to treat infectious diseases, including COVID-19, according to a news release by PhRMA.
The current COVID-19 pandemic has brought attention to antimicrobial resistance (AMR).
AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. A growing list of infections including pneumonia, tuberculosis, blood poisoning, gonorrhea and foodborne diseases are becoming harder, and sometimes impossible to treat as the microorganisms that cause these infections become more resistant to current medicines.
The biopharmaceutical industry recently launched the AMR Action Fund to work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline with the aim of bringing two to four new antimicrobials to patients by 2030.
The full infectious disease medicines in development report can be found here.
Alerts Sign-up